Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NUVB NASDAQ:PHAR NASDAQ:SANA NASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVBNuvation Bio$3.88+13.5%$2.52$1.54▼$4.09$1.33B1.365.05 million shs21.99 million shsPHARPharming Group$15.13+1.7%$11.69$6.73▼$17.08$1.05B0.0511,165 shs21,422 shsSANASana Biotechnology$2.96-0.7%$3.71$1.26▼$7.30$703.91M1.884.79 million shs3.61 million shsTILInstil Bio$31.50+3.9%$26.86$10.80▼$92.00$212.65M2.1699,744 shs185,281 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVBNuvation Bio+13.31%+30.45%+65.36%+57.13%+28.94%PHARPharming Group+1.75%+1.95%+23.11%+26.71%+102.82%SANASana Biotechnology-0.67%-3.27%-30.35%+4.23%-46.18%TILInstil Bio+3.89%+16.67%+19.73%-4.23%+113.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVBNuvation Bio$3.88+13.5%$2.52$1.54▼$4.09$1.33B1.365.05 million shs21.99 million shsPHARPharming Group$15.13+1.7%$11.69$6.73▼$17.08$1.05B0.0511,165 shs21,422 shsSANASana Biotechnology$2.96-0.7%$3.71$1.26▼$7.30$703.91M1.884.79 million shs3.61 million shsTILInstil Bio$31.50+3.9%$26.86$10.80▼$92.00$212.65M2.1699,744 shs185,281 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVBNuvation Bio+13.31%+30.45%+65.36%+57.13%+28.94%PHARPharming Group+1.75%+1.95%+23.11%+26.71%+102.82%SANASana Biotechnology-0.67%-3.27%-30.35%+4.23%-46.18%TILInstil Bio+3.89%+16.67%+19.73%-4.23%+113.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNUVBNuvation Bio 3.17Buy$7.3388.95% UpsidePHARPharming Group 3.00Buy$30.0098.28% UpsideSANASana Biotechnology 3.00Buy$8.00170.27% UpsideTILInstil Bio 3.00Buy$119.00277.78% UpsideCurrent Analyst Ratings BreakdownLatest TIL, PHAR, SANA, and NUVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.008/15/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.008/8/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $7.007/3/2025SANASana BiotechnologyMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.006/25/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$6.006/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$5.006/17/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.006/11/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$5.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNUVBNuvation Bio$7.87M168.79N/AN/A$1.37 per share2.83PHARPharming Group$297.20M3.49$0.07 per share205.86$3.25 per share4.66SANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ATILInstil BioN/AN/AN/AN/A$25.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNUVBNuvation Bio-$567.94M-$0.63N/AN/AN/A-1,413.43%-46.14%-36.04%11/5/2025 (Estimated)PHARPharming Group-$11.84M-$0.13N/A504.33N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)SANASana Biotechnology-$266.76M-$1.06N/AN/AN/AN/A-91.96%-43.07%11/14/2025 (Estimated)TILInstil Bio-$74.14M-$12.92N/AN/AN/AN/A-54.32%-33.65%11/12/2025 (Estimated)Latest TIL, PHAR, SANA, and NUVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025TILInstil Bio-$1.72-$3.24-$1.52-$3.24N/AN/A8/11/2025Q2 2025SANASana Biotechnology-$0.20-$0.16+$0.04-$0.39N/AN/A8/7/2025Q2 2025NUVBNuvation Bio-$0.17-$0.17N/A-$0.17$0.42 million$4.83 million7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNUVBNuvation BioN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNUVBNuvation Bio0.139.399.38PHARPharming Group0.382.792.07SANASana BiotechnologyN/A2.472.47TILInstil Bio0.6414.9714.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNUVBNuvation Bio61.67%PHARPharming Group0.03%SANASana Biotechnology88.23%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipNUVBNuvation Bio29.93%PHARPharming Group2.07%SANASana Biotechnology30.10%TILInstil Bio47.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNUVBNuvation Bio60342.27 million239.83 millionOptionablePHARPharming Group28068.51 million67.10 millionNot OptionableSANASana Biotechnology380237.81 million166.23 millionOptionableTILInstil Bio4106.75 million3.57 millionNo DataTIL, PHAR, SANA, and NUVB HeadlinesRecent News About These CompaniesInstil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the companyAugust 16, 2025 | finance.yahoo.comInstil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | finanznachrichten.deInstil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comInstil Bio Reports Promising Phase 2 Study ResultsAugust 11, 2025 | theglobeandmail.comInstil Bio stock rises after positive data for cancer therapy in ChinaJuly 31, 2025 | za.investing.comInstil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US testJuly 31, 2025 | fiercebiotech.comFImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in ChinaJuly 31, 2025 | globenewswire.comUS FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumoursJuly 4, 2025 | pharmabiz.comPInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...July 3, 2025 | manilatimes.netMInstil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - NasdaqJuly 3, 2025 | nasdaq.comInstil Bio Shares Climb After FDA Clears Tumor Treatment ApplicationJuly 2, 2025 | marketwatch.comInstil Bio stock jumps after FDA clearance of IND applicationJuly 2, 2025 | in.investing.comInstil Bio Shares Surge on FDA Clearance for Investigational Cancer TherapyJuly 2, 2025 | msn.comInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid TumorsJuly 2, 2025 | globenewswire.comInstil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should KnowJune 20, 2025 | zacks.comWall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a BetJune 16, 2025 | zacks.comInstil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody ProgramJune 11, 2025 | globenewswire.comAre You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great ChoiceJune 4, 2025 | zacks.comInstil Bio appoints new Chief Medical OfficerJune 4, 2025 | uk.investing.comInstil Bio appoints Jamie Freedman as Chief Medical OfficerJune 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTrump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 2025Can AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025Jackson Hole 2025: Fed’s Signal Could Shift Stocks FastBy Chris Markoch | August 20, 2025Big Rallies Brewing? 3 Analyst Favorites to Watch CloselyBy Nathan Reiff | August 18, 2025Lowe’s Builds Value for Investors: Still a Good Buy in 2025By Thomas Hughes | August 20, 2025TIL, PHAR, SANA, and NUVB Company DescriptionsNuvation Bio NYSE:NUVB$3.88 +0.46 (+13.48%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$3.92 +0.03 (+0.88%) As of 09/5/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Pharming Group NASDAQ:PHAR$15.13 +0.26 (+1.75%) Closing price 09/5/2025 03:58 PM EasternExtended Trading$15.13 0.00 (0.00%) As of 09/5/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Sana Biotechnology NASDAQ:SANA$2.96 -0.02 (-0.67%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.94 -0.02 (-0.84%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Instil Bio NASDAQ:TIL$31.50 +1.18 (+3.89%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$31.55 +0.05 (+0.16%) As of 09/5/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
